Skip to NavigationSkip to content

J&J pledges to end global TB pandemic

Published on 25/09/18 at 11:02am

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s most deadly infectious disease.

Through efforts to improve detection, broaden access to treatments, and accelerate R&D, the American pharma firm hope to save 1.8 million lives while preventing 12 million new TB infections, over the next ten years.

“TB is the world’s number one infectious killer, and TB and MDR-TB cause major devastation for people, communities and entire countries around the world,” Dr Paul Stoffels , Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, said in a statement. “The good news is TB is both preventable and treatable, and Johnson & Johnson is committed to doing everything we can to create a world free from TB. This new initiative will unleash the power of science and technology to forever change the trajectory of TB.”

While 10 million people fall ill with tuberculosis each year approximately 1.6 million die. However current treatments have particularly low cure rates and can equally lead to debilitating and even fatal side effects. The disease is also developing resistance to first line medicines as drug resistant TB now accounts for approximately one third of AMR related deaths.

As such, Jaak Peeters, Global Head, Johnson & Johnson Global Public Health, Janssen-Cilag GmbH, commented: “Our goal is to end the TB epidemic forever by finding and treating patients all over the world.”

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches